Reverse Vaccinology
Why in News?
British scientists recently used reverse vaccinology to take a major step towards a universal vaccine against pneumonia and meningitis caused by Streptococcus pneumoniae.
Concept & Origin
- Definition: An approach that shifts the vaccine pipeline from conventional laboratory biochemistry to in silico (computational) analysis of a pathogen's complete genome.
- Origin: The term was coined in 2000 by scientist Rino Rappuoli.
- First Success: It was successfully applied to develop a vaccine against Serogroup B Neisseria meningitidis (MenB), yielding the licensed vaccine Bexsero.
How the Mechanism Works?
- Genome Sequencing: The entire genetic blueprint (DNA/RNA) of the target pathogen is decoded.
- Bioinformatics Filtering: Computer software scans the genomic sequence to predict which genes encode proteins that sit on the virus or bacteria's surface.
- Epitope Prediction: Computational models analyze these surface proteins to identify specific segments (epitopes) that are most likely to trigger a strong human immune response.
- Targeted Synthesis: Only the genes for those selected, safe proteins are synthesized and tested in animal models to confirm they elicit protective antibodies.
Advantages Over Traditional Vaccinology
- Speed: Traditional vaccine development requires months or years of culturing live pathogens; reverse vaccinology can pinpoint targets within days of genome sequencing.
- Safety: Because the live, disease-causing pathogen is never handled or grown in massive quantities, the manufacturing process is inherently safer for scientists.
- Targets Unculturable Pathogens: Many dangerous bacteria and viruses cannot survive or replicate in laboratory media. Reverse vaccinology completely solves this limitation because it only needs genetic data.
- Broader Protection: Computational tools can find hidden, highly-conserved proteins shared across different mutant variants of a virus, laying the groundwork for "universal" vaccines.
Limitations & Challenges
- Limited to Protein Antigens: The technique is highly effective for identifying protein-based targets but cannot directly predict non-protein targets, such as polysaccharide/capsular components.
- Translational Gaps: Early-stage computer predictions (in silico) do not always guarantee that a human body will react with the same level of immunity during actual clinical trials.
